SAM
ABCL icon

Seelaus Asset Management’s AbCellera Biologics ABCL Stock Holding History

Seelaus Asset Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-10,000
Closed -$29.6K – 173
2024
Q2 		$29.6K Sell
10,000
-5,000
-33% -$18.9K 0.03% 169
2024
Q1 		$68K Buy
+15,000
New +$76.5K 0.07% 165

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Seelaus Asset Management's ABCL Position: Q3 2024 in Review

Seelaus Asset Management sold out of AbCellera Biologics (ABCL) in Q3 2024, closing a stake of 10,000 shares — an estimated $29.6K sold.

Seelaus Asset Management first reported a position in ABCL in Q1 2024 and held it in 2 quarters. The position peaked at $68K in Q1 2024. 139 funds tracked by Wall St. Rank hold ABCL as of Q3 2024.

  • Seelaus Asset Management reported no remaining AbCellera Biologics position as of Q3 2024 after selling out during the quarter.
  • Seelaus Asset Management sold 10,000 AbCellera Biologics shares in Q3 2024, an estimated $29.6K.
  • Seelaus Asset Management first reported a position in AbCellera Biologics in Q1 2024 and held it in 2 quarters.
  • Seelaus Asset Management's AbCellera Biologics position peaked at $68K in Q1 2024.
  • 139 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2024.

Based on Seelaus Asset Management's 13F filing for Q3 2024, filed 6 Nov 2024.